Literature DB >> 15534623

High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients.

T Qian1, X Guo, A D Levi, S Vanni, R T Shebert, M L Sipski.   

Abstract

STUDY
DESIGN: Prospective cohort study.
OBJECTIVE: Although Bracken et al have demonstrated a significant neuroprotective effect of high-dose intravenous (i.v.) methylprednisolone (MP) within 8 h post spinal cord injury (SCI), this practice has recently been challenged. We hypothesized it is possible that acute corticosteroid myopathy (ACM) may occur secondary to the MP. This pilot study was performed to test this hypothesis.
SETTING: University of Miami School of Medicine/Jackson Memorial Hospital, Miami VA Medical Center, FL, USA.
METHODS: Subjects included five nonpenetrating traumatic SCI patients, who received 24 h MP according to National Acute Spinal Cord Injury Studies (NASCIS) protocol, and three traumatic patients who suffered SCI and did not receive MP. Muscle biopsies and electromyography (EMG) were performed to determine if myopathic changes existed in these patients.
RESULTS: Muscle biopsies from the SCI patients who received 24 h of MP showed muscle damage consistent with ACM in four out of five cases. EMG studies demonstrated myopathic changes in the MP-treated patients. In the three patients who had SCI but did not receive MP, muscle biopsies were normal and EMGs did not reveal evidence of myopathy.
CONCLUSION: Our data suggest that MP in the dose recommended by the NASCIS may cause ACM. If this is true, part of the improvement of neurological recovery showed in NASCIS may be only a recording of the natural recovery of ACM, instead of any protection that MP offers to the injured spinal cord.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15534623     DOI: 10.1038/sj.sc.3101681

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  31 in total

Review 1.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

Review 2.  Molecular and cellular immune mediators of neuroprotection.

Authors:  Nicolas P Turrin; Serge Rivest
Journal:  Mol Neurobiol       Date:  2006-12       Impact factor: 5.590

Review 3.  Biomaterials for the central nervous system.

Authors:  Yinghui Zhong; Ravi V Bellamkonda
Journal:  J R Soc Interface       Date:  2008-09-06       Impact factor: 4.118

4.  Comparison of systemic and localized carrier-mediated delivery of methylprednisolone succinate for treatment of acute spinal cord injury.

Authors:  Maxim E Baltin; Diana E Sabirova; Elvira I Kiseleva; Marat I Kamalov; Timur I Abdullin; Natalia V Petrova; Nafis F Ahmetov; Oscar A Sachenkov; Tatiana V Baltina; Igor A Lavrov
Journal:  Exp Brain Res       Date:  2021-01-02       Impact factor: 1.972

5.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

Review 6.  Steroid myopathy: some unresolved issues.

Authors:  M A Minetto; F Lanfranco; G Motta; S Allasia; E Arvat; G D'Antona
Journal:  J Endocrinol Invest       Date:  2011-05       Impact factor: 4.256

Review 7.  Recent advances in nanotherapeutic strategies for spinal cord injury repair.

Authors:  Young Hye Song; Nikunj K Agrawal; Jonathan M Griffin; Christine E Schmidt
Journal:  Adv Drug Deliv Rev       Date:  2018-12-22       Impact factor: 15.470

Review 8.  Nanoparticle-mediated local delivery of Methylprednisolone after spinal cord injury.

Authors:  Young-tae Kim; Jon-Michael Caldwell; Ravi V Bellamkonda
Journal:  Biomaterials       Date:  2009-01-30       Impact factor: 12.479

Review 9.  Role of electrical stimulation for rehabilitation and regeneration after spinal cord injury: an overview.

Authors:  Samar Hamid; Ray Hayek
Journal:  Eur Spine J       Date:  2008-08-02       Impact factor: 3.134

Review 10.  Bench-to-bedside review: Diaphragm muscle function in disuse and acute high-dose corticosteroid treatment.

Authors:  Catherine Sh Sassoon; Vincent J Caiozzo
Journal:  Crit Care       Date:  2009-09-08       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.